Literature DB >> 9205635

Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine.

M J Kayath1, J G Vieira.   

Abstract

Acromegaly may induce abnormalities in bone metabolism; however, there are limited data related to bone mineral density (BMD) in this condition. To evaluate the effects of an excess of growth hormone/ insulin-like growth fractor I (GH/IGF-I) in the skeleton, we measured the BMD in spine and femoral region, total body calcium and body composition in 45 patients (24 females and 21 males) aged 21-77 years (median 43 years) with acromegaly for 11.4 +/- 7.5 years (range 0.5-26 years) using a dual-energy X-ray absorptiometer (Lunar DPX). Thirty-four patients had had hypogonadism for 8.6 +/- 6.5 years (1-24 years). Mean serum GH and IGF-I levels were respectively 159 +/- 183 micrograms/l and 843 +/- 497 micrograms/l. Total body calcium was increased in the acromegalics (males: 1272 +/- 217 g, range 916-1816 g; females: 1041 +/- 223 g, range 739-1609 g) when compared with normal individuals (males: 1115 +/- 144 g, range 856-1398 g; females: 909 +/- 144 g, range 511-1311 g; p = 0.01). The lean body mass was significantly higher in acromegalic patients (p < 0.001) compared with normal individuals. There was a tendency for a lower fat percentage in the acromegalics; however, this difference was not significant. Osteopenia (1 Z-score below the mean) was found in the spine in 20% (n = 9) of the patients, while BMD was decreased in the femoral region in only 8.8% (n = 4). The group with osteopenia had a greater duration of hypogonadism than the normal BMD group (14 +/- 11 years vs 4.4 +/- 4.0 years; p = 0.01). A negative correlation was also found between the duration of hypogonadism and BMD in spine (r = -0.4; p = 0.003) and femoral region (r = -0.37; p = 0.013). The hypogonadal patients had a lower BMD in spine (p < 0.005), but not in other regions analyzed. No correlation was found between duration of hypersomatotropism, GH/IGF-I levels and BMD. We conclude that the majority of patients with acromegaly have preserved BMD despite the presence of hypogonadism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205635     DOI: 10.1007/bf01622293

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  19 in total

1.  Monoclonal antibody-based immunoenzymometric assay for serum human growth hormone.

Authors:  J G Vieira; M T Lombardi; S K Nishida
Journal:  Braz J Med Biol Res       Date:  1990       Impact factor: 2.590

2.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.

Authors:  R W Furlanetto; L E Underwood; J J Van Wyk; A J D'Ercole
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

3.  Studies of 47Ca metabolism in acromegaly.

Authors:  N H Bell; F C Bartter
Journal:  J Clin Endocrinol Metab       Date:  1967-02       Impact factor: 5.958

4.  Effect of growth hormone on osteoblasts and demonstration of somatomedin-C/IGF I in bone organ culture.

Authors:  H Stracke; A Schulz; D Moeller; S Rossol; H Schatz
Journal:  Acta Endocrinol (Copenh)       Date:  1984-09

Review 5.  Growth hormone (replacement) therapy in adults: bone and calcium metabolism.

Authors:  E A van der Veen; J C Netelenbos
Journal:  Horm Res       Date:  1990

6.  Effects of short term administration of recombinant human growth hormone to elderly people.

Authors:  R Marcus; G Butterfield; L Holloway; L Gilliland; D J Baylink; R L Hintz; B M Sherman
Journal:  J Clin Endocrinol Metab       Date:  1990-02       Impact factor: 5.958

7.  Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.

Authors:  J S Finkelstein; A Klibanski; R M Neer; S L Greenspan; D I Rosenthal; W F Crowley
Journal:  Ann Intern Med       Date:  1987-03       Impact factor: 25.391

8.  Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism.

Authors:  T Diamond; L Nery; S Posen
Journal:  Ann Intern Med       Date:  1989-10-01       Impact factor: 25.391

9.  Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy.

Authors:  J S Johansen; S B Jensen; B J Riis; L Rasmussen; M Zachmann; C Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1990-07       Impact factor: 5.958

10.  Biochemical assessment of bone formation and resorption in acromegaly.

Authors:  S Ezzat; S Melmed; D Endres; D R Eyre; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958

View more
  13 in total

Review 1.  Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis?

Authors:  I Chiodini; V Trischitta; V Carnevale; A Liuzzi; A Scillitani
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

2.  Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.

Authors:  Marek Bolanowski; Jacek Daroszewski; Marek Medraś; Beata Zadrozna-Sliwka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 3.  Acromegalic osteopathy.

Authors:  G Mazziotti; F Maffezzoni; S Frara; A Giustina
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.

Authors:  J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2019-08-07       Impact factor: 4.256

5.  Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly.

Authors:  M Madeira; L V Neto; G A B de Lima; R O Moreira; L M C de Mendonça; M R Gadelha; M L F Farias
Journal:  Osteoporos Int       Date:  2010-03-20       Impact factor: 4.507

6.  Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength.

Authors:  S V Lim; M Marenzana; M Hopkinson; E O List; J J Kopchick; M Pereira; B Javaheri; J P Roux; P Chavassieux; M Korbonits; C Chenu
Journal:  Endocrinology       Date:  2015-02-03       Impact factor: 4.736

7.  Bone mineral density and circulating cytokines in patients with acromegaly.

Authors:  S Longobardi; C Di Somma; F Di Rella; N Angelillo; D Ferone; A Colao; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

Review 8.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

9.  Trabecular bone score as a skeletal fragility index in acromegaly patients.

Authors:  A R Hong; J H Kim; S W Kim; S Y Kim; C S Shin
Journal:  Osteoporos Int       Date:  2015-10-07       Impact factor: 4.507

10.  Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone.

Authors:  Peter Vestergaard; Leif Mosekilde
Journal:  Osteoporos Int       Date:  2003-11-19       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.